Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923 (XL139) when orally administered on a once daily schedule.

Inclusion Criteria:

• Subjects with advanced or metastatic solid tumors refractory to, or relapsed from, standard therapies or for which there is no known effective treatment
• Men and woman, 20 years of age and above

Exclusion Criteria:

• Subjects with symptomatic brain metastasis or active brain metastasis requiring treatments
• Inability to swallow oral medication
• Uncontrolled or significant cardiovascular disease
• Inadequate bone marrow function
• Inadequate hepatic function
• Inadequate renal function
• Pancreatitis